The New Way to protect. prevent.
We are working to change the world with the first universal influenza vaccine.
Progress to Date
Dr. Arthur Young builds mutant plasmid libraries for all eight flu segments, with every possible single nucleotide position mutated >100x over.
Plasmid libraries are used to produce virus mutant libraries, which are selected by two rounds of infection in cell culture. Sequencing of complex mutant sample after selection by high-throughput, next-generation sequencing (SOLiD).
First-of-kind NGS sequencing error-correction method successfully implemented, and sequencing data analyzed.
More than 50 individual mutants validated by reconstruction of mutant and testing in cell culture. Validation rate ~80% overall.
Initial list of 28 peptide epitopes delineated based on high invariance across entire stretch, high sequence conservation in publicly deposited flu samples, and predicted binding to HLA's (NetMHCpan).
Nicholas Wu, graduate student protege of Dr. Young, repeats selection and sequencing utilizing improved molecule (barcode) tagging and using Illumina HiSeq2000 (superior to SOLiD). Obtains deeper coverage from sequencing. After data analysis, vaccine epitope list expanded to 45 peptides.
Provisional patent (UCLA Case No. 2013-10-03) filed for 45 peptides. InvVax takes out 12-month exclusive option to explore applicability of theoretically superior vaccine epitopes via proof-of-principle in vivo (mouse) vaccine studies.
Accomplished first of two animal milestones in HLA-transgenic mice, proving a robust immune response for an HLA-B7 peptide.
Currently working to demonstrate efficacy of select peptides and protection against lethal infection in mouse.